**INTRODUCTION**

HIV-infected patients, especially on a long duration of antiretroviral therapy (ART), are now facing newer challenges in terms of developing pathological aberrations of fat metabolism and redistribution. The two terms, HIV-associated adipose redistribution syndrome (HARS) and HIV-associated lipodystrophy syndrome (HALS), possibly have the same connotation to describe an acquired (? iatrogenic) state of partial derangement in fat accumulation along with significant metabolic risks.[1] Lipodystrophy (changes in fat distribution) is a clinical diagnosis and mostly subjective as standardized diagnostic criteria have not yet been defined. That is why, the exact prevalence rate of HALS has not been precisely quantified since it was first reported 13 years ago.[2] HIV-associated lipodystrophy involves fat redistribution (lipodystrophy), fat loss from the face, buttocks, and extremities (lipoatrophy), and mixed fat disturbances (lipodystrophy and lipoatrophy). They often have insulin resistance, type 2 diabetes, and elevated plasma lipid concentrations. The combination of hyperlipidemia, insulin resistance, and visceral fat accumulation resembles the cluster of abnormalities described in the “metabolic syndrome” associated with increased cardiovascular risk. HALS harbors endothelial dysfunction and accelerated atherosclerosis.[3] HALS closely mimics obesity. Skeletal muscle leptin resistance can potentially contribute to muscular fatty acid accumulation in common human obesity, simulating the muscle steatosis found in lipodystrophy patients. Visceral fat accumulation in obesity also resembles lipodystrophy in HIV.

Hormone therapies in the treatment of HALS have been explored recently. Anabolic steroids, growth hormone (GH), growth hormone releasing hormone (GHRH), recombinant human leptin, and adiponectin (synthetic form unavailable) are the candidates for hormone therapy. For the last 15 years, much has been known about leptin biology. However, it is only recently that the leptin–hypothalamic axis has newly been explored which regulates insulin and glucose metabolism independent of its effect on adiposity. This article affords a comprehensive review of leptin therapy, a new strategy now in clinical trials, and its beneficial role in HIV patients in correction of metabolic complications related to HIV therapy.

**Key words:** Antiretroviral therapy, HIV, leptin, lipodystrophy, metabolic syndrome
WHAT IS LEPTIN?

Leptin is a 167-amino acid product of human leptin gene on chromosome no. 7, originally identified in 1995 through positional cloning of *ob/ob* mice, a mouse model of obesity discovered serendipitously at Jackson laboratories where these mice were found having complete leptin deficiency causing hyperphagia, severe obesity, diabetes, infertility, and other neuroendocrine abnormalities.[4-7] This discovery led to further research works that revealed important role of leptin in energy homeostasis, weight regulation, immunity, and neuroendocrine function.

Leptin is secreted in a pulsatile fashion by white adipose tissue and is also found in circulation and cerebrospinal fluid.[9] Its circulatory levels positively correlate with the amount of body fat and have significant diurnal variation, with higher levels in the evening and early morning hours. Leptin mediates its effects by binding to specific leptin receptors (ObRs) expressed in brain and peripheral tissues. The ObRa isoform (short leptin receptor isoform) is found to have an important role in leptin transport across the blood–brain barrier, while the ObRb isoform (long leptin receptor isoform), also known as LepR-l or LepRb, is thought to mediate signal transduction with its strong expression in hypothalamus. Leptin in brain (both in parenchyma and cerebrovascular fluid) is derived from peripheral circulation and local synthesis. Short isoform of leptin receptors on vascular endothelium and epithelium of choroid plexus transports leptin across the blood–brain barrier.[9] It has been seen that both hypo- and hyperleptinemia are associated with reduced leptin entry into the brain.

LEPTIN AND METABOLIC SYNDROME – CLINICAL UTILITY

The discovery of leptin has advanced our understanding of metabolic diseases. Its identification has revealed a new neuroendocrine system regulating body weight. Complete leptin deficiency from mutations in leptin gene, as found in some rare genetic conditions, presents with infantile morbid obesity and associated endocrinial dysfunction including insulin resistance and hypogonadotropic hypogonadism.[10,11] Severe lipodystrophy, both genetic and acquired (as in HALS), is another hypoleptinemic state characterized by adipose tissue loss, hypertriglyceridemia, severe insulin resistance, and even overt diabetes mellitus. Recombinant human leptin replacement therapy at physiologic replacement dose in both the situations described above has improved hormonal abnormalities, glycemic control, and dyslipidemia.[12-14] In the management of HIV lipodystrophy and metabolic syndrome, recombinant human leptin (metreleptin) has recently been extensively studied in the context of many open-label, clinical trials. Since no approved effective treatment exists for alleviating the major health problems associated with HALS, leptin therapy, in this context, stands out to be essentially promising which will be reviewed next.

Though most of the therapeutic trials with leptin started focusing primarily on obesity, the majority of obese subjects were proved to be leptin resistant with high serum leptin levels, which establishes that obesity is the result of hormone resistance.[15] Leptin treatment resulted in weight loss only in a subset of obese patients, and was therefore not found to be of much help in treating obesity in general. Again, there is substantial variability of leptin levels at a given body mass index or percent fat and approximately 10–15% of obese subjects have endogenous levels of leptin that are indistinguishable from lean patients.[10]

“Leptin insufficiency syndrome,” a concept promulgated a few years ago based mainly on strong experimental support has replaced “leptin resistance” as causal in the etiology of diabetes and obesity.[17] The leptin insufficiency syndrome manifests due to hypoleptinemia and/or decreased leptin delivery to the hypothalamus by transport restrictions across blood–brain barrier in obese, hyperleptinemic state. Leptin receptor downregulation at the blood–brain interphase and increased binding of leptin to C-reactive protein (CRP) in peripheral circulation are the two important endogenous defense mechanisms that operate simultaneously in hyperleptinemic state to restrict leptin supply to the hypothalamus.

Leptin–hypothalamic axis has a crucial role in regulating pancreatic insulin secretion and glucose metabolism independent of its effect on adiposity. Newer experiments revealed multiple novel mechanisms whereby central leptin insufficiency and peripheral hyperleptinemia concomitantly participate in the causation of metabolic syndrome. Acute inhibition of insulin secretion by central administration of leptin has recently been reported. Enhanced leptin signaling in selected hypothalamic sites such as the medial preoptic area (MPOA), paraventriculare hypothalamus (PVN), ventromedial hypothalamus (VMH), or arcuate nucleus (ARC) experimentally corrects hyperinsulinemia and averts the development of insulin resistance.[18] Several tract tracing studies including those with microinjection of leptin transgene in hypothalamic sites imply that hypothalamus sends efferent insulin inhibiting signals to pancreas by hypothalamic neuropeptide Y NPY-ergic system bypassing the dorsal vaginal neurons.[19] Recent studies also detected insulin-independent role of leptin in hypothalamic glucose regulation possibly by accelerating glucose metabolism in brown adipose tissue, liver, skeletal muscles, and fat cells.[20]
Various attempts to increase leptin delivery to hypothalamus and extrahypothalamic sites with daily injection or continuous infusion, both systemically and centrally (intracerebro-ventricular or intrathecal), in pharmacological doses over short periods have been quite satisfactory in animal models. Final modality of leptin delivery is central leptin gene therapy. This one-time neurotherapy with its durable antidiabetic efficacy offers a potential substitution for insulin therapy in metabolic syndrome in near future.

**Leptin in HIV Disease**

It is evident that only hypooleptinemic HIV-infected patients are the actual beneficiaries and are selected for recombinant leptin treatment trials to combat metabolic syndrome. As serum leptin level varies in general population depending on age, sex, feeding status, body habitus, and circadian cycle, hypooleptinemia is usually considered when serum leptin level is <3 ng/ml in men and <4 ng/ml in women. Fasting leptin levels have been correlated with total body fat concentrations in HIV-infected patients. Nagy et al. found that leptin levels were lowest in HIV patients exhibiting lipoatrophy, intermediate in those with mixed lipodystrophy or normal body habitus, and highest in those with lipohypertrophy. These findings suggest a reduction in leptin synthesis in those having lipoatrophy with reduced subcutaneous adipose tissue and excess circulating levels of leptin might be due to leptin resistance in those with visceral adipose tissue hypertrophy. This leptin-resistant state might also be related to metabolic syndrome and insulin resistance seen in HIV patients with lipohypertrophy. Untreated HIV infection is a progressive cellular immunodeficiency state with anorexia, weight loss, malnutrition, and opportunistic infections. Though leptin was shown to induce anorexia and augment T helper cell (Th1) population, most of the patients with HIV-associated wasting were found to have decreased serum leptin levels and that low value was proportional to the degree of fat loss.

Leptin levels in HIV patients have been shown to be higher in general female population than males for any given measure of adipose mass. Leptin levels also rise more rapidly in women than men with increase in proportion of body fat. In contrast, the Nigerian study revealed lower level of leptin among female HIV patients as compared to male patients. Reversal of this sex difference may contribute to more wasting in female AIDS patients as most of the HIV wasted patients were females. Most studies in humans and animal models also found a positive correlation between the number of CD4 T cells and leptin levels in healthy controls, but this correlation was blunted in HIV patients.

**HIV Lipodystrophy**

The morphologic and metabolic changes associated with ART have led to the development of HALS characterized by peripheral lipoatrophy (fat loss in face, arms, legs, buttocks), localized fat accumulation, hyperlipidemia, insulin resistance, and hyperglycemia. Hepatic steatosis may also occur, but acanthosis nigricans seems extremely rare in contrast to congenital lipodystrophy. The prevalence of HALS in patients taking ART has been reported to be up to 80% with increased cardiovascular risks. HALS is thought to be multifactorial with complex interactions of drugs, viral and host-related factors. Although ART with protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NRTIs) are said to be the most compelling risk factors, gender, altered adipose gene expression, altered adipokines, mitochondrial toxicity, HIV-1 associated protein, and genetic polymorphism are some of the important pathophysiologic mechanisms underlying its development. Cross-sectional studies have shown low levels of leptin and adiponectin in HALS, which are closely and inversely correlated with dyslipidemia and insulin resistance. Animal experiments also demonstrated that combined administration of both leptin and adiponectin fully normalized insulin sensitivity in hypooleptinemic and hypoadiponectinemic lipoatrophic mice.

Walker and Brinkman have shown a relation between
peripheral lipoatrophy and mitochondrial toxicity in HIV patients. Mitochondrial toxicity occurs due to inhibition of mitochondrial DNA polymerase-γ by several antiretrovirals with variable affinity for the enzyme. In vitro studies using HepG2 human hepatoma cells showed the worst effects with zalcitabine, didanosine, and stavudine in reducing order causing marked hyperlactatemia and multiorgan toxicities involving liver, pancreas, peripheral nerves, and skeletal muscles.

Altered levels of adipokines and proinflammatory cytokines (as demonstrated in in vitro murine and human adipocyte cell lines and in vivo studies with NRTIs and PIs) may be responsible for insulin resistance seen in lipodystrophy. PI have been found to cause reduction in lipid accumulation in adipocytes, increase in adipocyte apoptosis, inhibition of insulin-stimulated glucose uptake [inhibiting glucose transporter type 4 (GLUT4)], induction of interleukin-6 (IL)-6, TNF-α, reduction in gene expression, and secretion of adiponectin, all thereby inducing insulin resistance.

Lipoatrophic fat from HALS patients demonstrated reduced adipogenic transcription factors like sterol regulatory element-binding protein 1c (SREBP-1c), CAAT enhancer binding protein-α (C/EBP-α), and peroxisome proliferator activated receptor-γ (PPAR-γ) – all involved in adipocyte differentiation along with reduced mRNA expression of adiponectin and leptin. Some studies have shown similar changes in HIV patients who were not being treated with ART, suggesting that HIV may have a direct role in the mechanism of lipodystrophy. Proteasome dysfunction has been implicated in the pathogenesis of HALS. PIs have also been found to inhibit proteasome chymotryptic activity, leading to endoplasmic reticulum stress response to misfolded proteins.

**How Does Leptin Benefit HIV Lipodystrophy?**

Several small open-label clinical trials have demonstrated that patients with severe leptin deficiency from congenital and non–HIV-related acquired generalized lipodystrophy could be benefited by the physiological replacement doses of leptin (0.04–0.08 mg/kg s.c. daily) in terms of improvements in insulin sensitivity, glucose tolerance, levels of fasting glucose, and HbA1c, hypertriglyceridemia, transaminitis, and changes in body composition (weight loss with decreased adipose tissue and lean mass), and thus the need for insulin or oral hypoglycemic agents could be lessened with the help of leptin. Similarly, trial-based recombinant human leptin therapy has been tried in hypoleptinemic patients with HIV-associated lipodystrophy, and leptin was well tolerated with marked improvement in fasting insulin levels, insulin resistance, high density lipoprotein (HDL) cholesterol, and truncal obesity. Furthermore, the improvements in insulin resistance reported in patients with HALS treated with metreleptin provide an advantage over GH replacement therapy as GH treatment is associated with glucose intolerance. But only those patients who have an absolute leptin deficiency (usually <3 ng/ml in men and <4 ng/ml in women) would enjoy the dramatic treatment benefit with leptin.

Riddle et al. in the in vitro animal (ritonavir-treated mice) study with leptin showed reversal of raised total cholesterol, reduction in ritonavir-induced interscapular fat, and improved hepatic steatosis. Lee et al. observed similar beneficial effect of recombinant human leptin therapy (0.04 mg/kg s.c. daily for 2 months) in 7 men with HALS, low leptin, and hypertriglyceridemia. Beneficial response was also reported by Mulligan et al. with recombinant methionyl human leptin for 6 months (0.01 mg/kg s.c. twice daily for 3 months, followed by 0.03 mg/kg s.c. twice daily for 6 months) among eight hypoleptinemic male patients with HALS. Leptin treatment was associated with around 32% decrease in visceral fat, improvement in insulin sensitivity, fasting insulin and glucose levels, and HDL cholesterol, and 15–20% decrease in low density lipoprotein (LDL) cholesterol, with considerable decrease in triglyceride, whole body lipolysis, and free fatty acid levels.

It has been proposed that leptin may improve insulin resistance through several mechanisms such as: (1) activating insulin signaling pathways including skeletal muscle phosphatidylinositol 3-kinase and AMP-activated protein kinase (AMPK); (2) preventing “lipotoxicity”: decreasing intrahepatic and intramyocellular fat by activating fatty acid oxidation in skeletal muscles; (3) decreasing caloric intake; and (4) decreasing body weight and fat mass. Mulligan and Khatami et al. also suggested that leptin can improve hepatic insulin sensitivity possibly irrespective of its effect on peripheral insulin sensitivity and independent of reduction in visceral adipose tissue. In spite of the above-mentioned small observation-based hypotheses, the precise mechanisms underlying leptin’s beneficial role in HALS is yet to be established.

**Leptin Versus Other Available Treatment Modalities in HALS**

Leptin as a monotherapy or an insulin-sparing agent in controlling metabolic components of HALS is still a remote theoretical possibility. In spite of its successful placebo-controlled trials, leptin therapy has not yet been compared head-to-head with any of the many other available treatment modalities like metformin, thiazolidinediones...
(TZDs) – rosiglitazone, pioglitazone, GH, or synthetic GHRH (sermorelin, tesamorelin).[56–58] It is also not known whether a combination of leptin with any of the above-mentioned drugs can work even better than a single agent. Just like leptin, metformin and TZDs (which also increase adiponectin level) improve insulin sensitivity, but GH or synthetic GHRH is diabetogenic. Neither GH nor GHRH analogs are approved by FDA for the treatment of HALS. As individuals with HALS tend to be GH deficient, GH replacement can be a promising treatment option in this patient population. As leptin acts independent of the GH and insulin-like growth factor-1 (IGF-1) system, a combination therapy with leptin and GH or GHRH analogs could potentially have additive metabolic benefits without adversely affecting glucose intolerance.[59,60] Adiponectin, a 244 amino acid protein, is another endogenous insulin sensitizer that reduces gluconeogenesis primarily by stimulating adiponectin receptor 2 (ADIPOR2) and activation of AMPK phosphorylation. It also increases fatty acid oxidation in muscle via ADIPOR1 whose stimulation of insulin and leptin signaling that promotes increased insulin sensitivity and reduced food intake.[61,62] Adiponectin levels are also low in patients with HALS, and hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and adipose tissue redistribution in HIV-infected patients on antiretroviral medications. Although leptin or adiponectin alone improves insulin resistance in mouse models of lipodystrophy, the combined administration of both hormones fully normalizes insulin sensitivity in animal models. But no synthetic form of adiponectin is yet available for treatment in human beings. Adiponectin as well as its receptors ADIPOR1 and ADIPOR2 are attractive future targets for drug development in HALS.

**Limitations of Leptin Therapy: Questions Unanswered?**

Recombinant human leptin, still an investigational product, is not yet available commercially in the market for the patients suffering from HIV-associated lipodystrophy and metabolic complications. The scope for its therapeutic utility is grossly suffering from lack of longer and larger well-furnished clinical trials from many countries worldwide. Leptin levels in circulation of HIV patients under various other treatments are largely unknown, which has become a major limitation of leptin therapy. Many questions regarding leptin replacement therapy have thus remained yet unanswered. Controversies and queries remain about the optimal dose, route of administration (peripheral vs. central leptin therapy), number of daily administrations, duration of therapy, need to follow-up the circulating leptin level, scope for combination therapy, possible adverse effects after long-term usage, and last but not the least, expected benefit in patients with relatively higher leptin levels. Naturally, additional information are needed further for the basic clarity of this unclear practical scenario.

**Acknowledgment**

We are indebted to every member of the Department of Medicine and Endocrinology, NRSMCH.

**References**

1. Leow MK, Addy CL, Mantzoros CS. Clinical review 159: Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: Clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab 2003;88:1961-76.
2. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352:48-62.
3. Depaon R, Chesse S, Sudre P, Rodondi N, Doser N, Chave JP, et al.; Swiss HIV Cohort Study. 2001 Premature atherosclerosis in HIV-infected individuals—focus on protease inhibitor therapy. AIDS 2001;15:329-34.
4. Zhang Y, Proenca P, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32.
5. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-6.
6. Pellegromer MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269:540-3.
7. Campbell LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: Evidence for a peripheral signal linking adiposity and central neural networks. Science 1995;269:546-9.
8. Licinio J, Mantzoros C, Negrao AB, Cizza G, Wong ML, Bongiorno PB, et al. Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. Nat Med 1997;3:575-9.
9. Hileman SM, Pierroz DD, Masuzaki H, Bjorbaek C, El-Haschimi K, Banks WA, et al. Characterization of short isoforms of the leptin receptor in rat cerebral microvessels and brain uptake of leptin in mouse models of obesity. Endocrinology 2002;143:775-83.
10. Farooqi IS, Wangensteen T, Collins S, Kimber W, Matarese G, Keogh JM, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 2007;356:237-47.
11. Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet 1998;18:213-5.
12. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002;109:1345-50.
13. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005;54:1994-2002.
14. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346:570-8.
15. Ioffe E, Moon B, Connolly E, Friedman JM. Abnormal regulation of the leptin gene in the pathogenesis of obesity. Proc Natl Acad Sci U S A 1998;95:11882-7.
16. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, et al. Leptin levels in human and rodent: Measurement of plasma
leptin and oR NA in obese and weight-reduced subjects. Nat Med 1995;1:1155-61.

17. Kalra SP. Central lepTin insufﬁciency syndrome: An interactive etiology for obesity, metabolic and neural diseases and for designing new therapeutic interventions. Peptides 2008;29:127-38.

18. Beretta E, Dube MG, Kalra PS, Kalra SP. Long-term suppression of weight gain, adiposity, and serum insulin by central leptin gene therapy in prepubertal rats: Effects on serum ghrelin and appetite regulating genes. Pediatr Res 2002;52:189-98.

19. Boghossian S, Lecklin A, Dube MG, Kalra PS, Kalra SP. Increased leptin expression in the dorsal vagal complex suppresses adiposity without affecting energy intake and metabolic hormones. Obesity 2006;14:1003-9.

20. Chinookoswong N, Wang JL, Shi ZQ. Leptin restores euglycemia and normalizes glucose turnover in insulin-deﬁcient diabetes in the rat. Diabetes 1999;48:1487-92.

21. Kalra SP. Pivotal role of leptin-hypothalamus signaling in the etiology of diabetes uncovered by gene therapy: A new therapeutic intervention? Gene Ther 2011;18:319-25.

22. Tsiodras S, Mantzoros C. Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications. Am J Infect Dis 2006;2:141-52.

23. Nagy GS, Tsiodras S, Martin LD, Avhingsanon A, Gavrila A, Hsu WC, et al. Human immunodeficiency virus type 1-related lipatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis 2003;36:795-802.

24. Koutika P, Caravan B, Breu J, Torriani M, Kissko J, Grinspon S. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: A randomized controlled trial. JAMA 2004;292:210-8.

25. Simon V, Ho DD, Karim QA. HIV/AIDS epidemiology, pathogenesis, prevention and treatment. Lancet 2006;368:499-504.

26. Ballinger A, Kelly P, Hallybartun E, Besser R, Farthing M. Plasma leptin in chronic inflammatory bowel disease and HIV: Implications for the pathogenesis of anorexia and weight loss. Clin Sci 1998;94:479-83.

27. Onyemelukwe GC, Ogoina D, Bakari AG. Serum Leptin Levels in Antiretroviral Therapy Naïve HIV-1 Infected Patients in Zaria, Nigeria. Int J Endocrinol Metab 2009;3:162-9.

28. Grunfeld C, Fang M, Shigenaga MK, Jensen P, Lallone R, Friedman J, et al. Human immunodeficiency virus type 1-associated metabolic syndrome: Physiologic and Therapeutic Implications. Am J Infect Dis 2006;2:141-52.

29. Simon V, Ho DD, Karim QA. HIV/AIDS epidemiology, pathogenesis, prevention and treatment. Lancet 2006;368:499-504.

30. Ballinger A, Kelly P, Hallybartun E, Besser R, Farthing M. Plasma leptin in chronic inflammatory bowel disease and HIV: Implications for the pathogenesis of anorexia and weight loss. Clin Sci 1998;94:479-83.

31. Kennedy A, Gettys TW, Watson P, Wallace P, Ganaway E, Qin P, et al. The metabolic signiﬁcance of leptin in human: Gender based differences in relationship to adiposity, insulin sensitivity and energy expenditure. J Clin Endocrinol Metab 1997;82:1293-300.

32. Kino T, Gragerov A, Kopp JB, Stauber RH, Pavlakis GN, Chrousos GP. The HIV-1 virion-associated protein VPR is a coactivator of the human glucocorticoid receptor. J Exp Med 1999;189:51-62.

33. Kino T, Chrousos GP. Human immunodeﬁciency virus type 1 accessory protein Vpr: A causative agent of the AIDS-related insulin resistance/lipodystrophy syndrome? Ann NY Acad Sci 2004;1024:153-67.

34. Rietelsiel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, Gertner J, et al. Assessment of growth hormone dynamics in human immunodeﬁciency virus-related lipodystrophy. J Clin Endocrinol Metab 2001;86:504-10.

35. Engelson ES, Glesby MJ, Mendez D, Albu JB, Wang J, Heymsfield SB, et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Deﬁc Syndr 2002;30:379-91.

36. Schwarze JM, Mulligan K, Lee J, Lo JC, Wen M, Noor MA, et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2002;87:942.

37. Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS. Hypoaldosteronism is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeﬁciency virus-infected patients treated with high dose antiretroviral therapy. J Clin Endocrinol Metab 2003;88:627-36.

38. Yamauchi T, Komon J, Waki H, Terauchi Y, Kubota N, Harada K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipodystrophy and obesity. Nat Med 2001;7:941-6.

39. Walker UA, Brinkman K. NRTI induced mitochondrial toxicity as a mechanism for HAART related lipodystrophy: Fact or ﬁction? HIV Med 2001;2:163-5.

40. Squires KE. An introduction to nucleoside and nucleotide analogues. Antivir Ther 2001;6 Suppl 3:S1-14.

41. Walker UA, Venhoff N, Koch EC, Olschewski M, Schneider J, Setzer B. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir Ther 2003;8:463-70.

42. Walker UA, Bickel M, Lutke Volksbeek SI, Ketelsen UP, Schöler H, Setzer B, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Deﬁc Syndr 2002;29:117-21.

43. Venhoff N, Setzer B, Melkaoui K, Walker UA. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther 2007;12:1075-85.

44. Jones SP, Janneh O, Back DJ, Firdmohamed M. Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antivir Ther 2005;10:207-19.

45. Janneh O, Hoggard PG, Tija JF, Jones SP, Khoo SH, Maher B, et al. Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. Antivir Ther 2003;8:417-26.

46. Kim RJ, Wilson CG, Wabitsch M, Lazar MA, Steppan CM. HIV protease inhibitor speciﬁc alterations in human adipocyte differentiation and metabolism. Obesity (Silver Spring) 2006;14:1002.

47. Noor MA, Flint OP, Maaf JF, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: Demonstrable differences in vitro and clinically. Acquir Immune Deﬁc Syndr 2006;20:1813-21.

48. Lagathu C, Kim M, Maachi M, Vigouroux C, Cervera P, Capeau J, et al. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Biochimie 2005;87:65-71.

49. Parker RA, Flint OP, Mulvey R, Elosua C, Wang F, Fenderson W, et al. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol Pharmacol 2005;67:1909-19.

50. Andreev VP, Paz-Filho G, Wong ML, Licinio J. Deconvolution of insulin secretion, insulin hepatic extraction post-hepatic delivery rates and sensitivity during 24-hour standardized meals: Time course of glucose homeostasis in leptin replacement treatment. Horm Metab Res 2009;41:142-51.
and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 2007;92:532-41.

52. Javor ED, Ghany MG, Cochran EK, Oral EA, DePaoli AM, Premkumar A, et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005;41:753-60.

53. Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros CS. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipodystrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006;91:2605-11.

54. Mulligan K, Khatami H, Schwarz JM, Sakkas GK, DePaoli AM, Tai VW, et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with HIV-associated lipodystrophy and hypeleptinemia. J Clin Endocrinol Metab 2009;94:1137-44.

55. Bluher S, Mantzoros CS. Leptin in humans: Lessons from translational research. Am J Clin Nutr 2009;89:991S-7.

56. Lo J, You SM, Canavan B, Liebau J, Beltrani G, Koutkia P, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: A randomized controlled trial. JAMA 2008;300:509-19.

57. Kotler DP, Muurahainen N, Grundfeld C, Wanke C, Thompson M, Saag M, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004;35:239-97.

58. Gavrila A, Hsu W, Tsiodras S, Doweiko J, Gautam S, Martin L, et al. Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: A 2 × 2 factorial, randomized, double-blinded, placebo-controlled trial. Clin Infect Dis 2005;40:745-9.

59. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359-70.

60. Brennan AM, Lee JH, Tsiodras S, Chan JL, Doweiko J, Chimenti SN, et al. r-metHuLeptin improves highly active antiretroviral therapy-induced lipodystrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: Observational and interventional studies in humans. Eur J Endocrinol 2009;160:173-6.

61. Kinlaw WB, Marsh B. Adiponectin and HIV-lipodystrophy: Taking HAART. Endocrinology 2004;145:484-6.

62. Krälsch S, Bluher M, Paschler R, Stumvoll M, Fasshauer M. Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome. Mini Rev Med Chem 2007;7:39-45.

Cite this article as: Sinha U, Sinharay K, Sengupta N, Mukhopadhyay P. Benefits of leptin therapy in HIV patients. Indian J Endocr Metab 2012;16:637-43.

Source of Support: Nil, Conflict of Interest: None declared.